Clinical trials have a long history dating back to Avicenna in the 11th century who established principles for testing drug effectiveness. Modern clinical trials involve extensive pre-clinical testing followed by 4 phases of human trials. Phase I trials in healthy volunteers establish safety. Phase II trials in patients provide preliminary efficacy and safety data. Phase III trials involve thousands of patients to confirm efficacy and monitor side effects. Phase IV occurs after approval to further monitor long-term safety. Randomization, blinding, and use of control groups aim to reduce bias in trial design and interpretation of results.
Turacoz Healthcare Solutions provides clinical research and regulatory writing services for pharmaceutical companies. We tell you about the different components of a clinical study protocol, the document which is prepared before beginning of any clinical trial. To know more info, visit- goo.gl/C1ec0L or write to us at hello@turacoz.in and call us 011-40584280.
Turacoz Healthcare Solutions provides clinical research and regulatory writing services for pharmaceutical companies. We tell you about the different components of a clinical study protocol, the document which is prepared before beginning of any clinical trial. To know more info, visit- goo.gl/C1ec0L or write to us at hello@turacoz.in and call us 011-40584280.
An overview of ICH-GCP guidelines of clinical trials.
Good clinical practice (GCP): a standard for the design , conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials that provides assurance that the data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial subjects are protected.
ICH-GCP is an International Conference on Harmonization Good Clinical Practice.
The guideline was developed with consideration of the current good clinical practices of the European union, Japan, and the United States, as well as those of Australia, Canada, the Nordic countries and the world health organization
“CSR is a detailed regulatory document which gives the information about the methods and results (related to efficacy and safety) of a clinical trial. CSRs are created as a part of the process of submitting applications to the Regulatory Authorities for new medical treatments and for its approval. CSRs can be full, abbreviated, synopsis, supplementary, observational etc as per the results and requirements”.
Table of contents
-Definition of CRF
-What is CRF
-Types & Methods of filling of CRF
-CRF Input team
-CRF Approval team
-Review team
-Facts about CRF
-Purpose of CRF
-CRF Development process & Guidelines
-Elements of CRF
-CRF Design
-CRF completion checklist
-CRF Design tools
-CRF use
-GCP connection
The safety monitoring in a clinical trail accompanies by common practices in safety monitoring, communicating safety information among stakeholders in a clinical trail.
changes and yet everything is completely different."
Clinical Research has evolved a long way since its inception, whether documented or not. It traverses a long and amazing journey. The recorded history of clinical trials dates back to the biblical descriptions of 500 BC. The journey encompasses from dietary therapy - legumes and lemons - to drugs.
Clinical study on human subjects according to all guidelines to form a ideal protocol and requirement to conduct clinical trial with very efficient way mainly considering to India and ICH associated countries
A sponsor in literal terms is defined as an individual or a company or an institution that takes the responsibility for the initiation, management and/or financing of a clinical study.
In case an investigator independently initiates and takes full responsibility for a trial, he/she automatically assumes the role of a sponsor.
Investigator: A person responsible for the conduct of the study at the trial site.
Investigator is a person responsible for the rights, health and welfare of the study subjects.
Essential Documents For the Conduct of Clinical TrialClinosolIndia
The conduct of a clinical trial involves the generation and maintenance of various essential documents to ensure compliance with regulatory requirements and Good Clinical Practice (GCP) guidelines. These documents serve as a record of the trial and provide evidence of the study's conduct, integrity, and participant protection. Here are some essential documents commonly required for the conduct of a clinical trial
An overview of ICH-GCP guidelines of clinical trials.
Good clinical practice (GCP): a standard for the design , conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials that provides assurance that the data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial subjects are protected.
ICH-GCP is an International Conference on Harmonization Good Clinical Practice.
The guideline was developed with consideration of the current good clinical practices of the European union, Japan, and the United States, as well as those of Australia, Canada, the Nordic countries and the world health organization
“CSR is a detailed regulatory document which gives the information about the methods and results (related to efficacy and safety) of a clinical trial. CSRs are created as a part of the process of submitting applications to the Regulatory Authorities for new medical treatments and for its approval. CSRs can be full, abbreviated, synopsis, supplementary, observational etc as per the results and requirements”.
Table of contents
-Definition of CRF
-What is CRF
-Types & Methods of filling of CRF
-CRF Input team
-CRF Approval team
-Review team
-Facts about CRF
-Purpose of CRF
-CRF Development process & Guidelines
-Elements of CRF
-CRF Design
-CRF completion checklist
-CRF Design tools
-CRF use
-GCP connection
The safety monitoring in a clinical trail accompanies by common practices in safety monitoring, communicating safety information among stakeholders in a clinical trail.
changes and yet everything is completely different."
Clinical Research has evolved a long way since its inception, whether documented or not. It traverses a long and amazing journey. The recorded history of clinical trials dates back to the biblical descriptions of 500 BC. The journey encompasses from dietary therapy - legumes and lemons - to drugs.
Clinical study on human subjects according to all guidelines to form a ideal protocol and requirement to conduct clinical trial with very efficient way mainly considering to India and ICH associated countries
A sponsor in literal terms is defined as an individual or a company or an institution that takes the responsibility for the initiation, management and/or financing of a clinical study.
In case an investigator independently initiates and takes full responsibility for a trial, he/she automatically assumes the role of a sponsor.
Investigator: A person responsible for the conduct of the study at the trial site.
Investigator is a person responsible for the rights, health and welfare of the study subjects.
Essential Documents For the Conduct of Clinical TrialClinosolIndia
The conduct of a clinical trial involves the generation and maintenance of various essential documents to ensure compliance with regulatory requirements and Good Clinical Practice (GCP) guidelines. These documents serve as a record of the trial and provide evidence of the study's conduct, integrity, and participant protection. Here are some essential documents commonly required for the conduct of a clinical trial
When a new drug/device/surgical procedure/treatment or other potential medical innovation is developed it must be thoroughly tested to ensure that it is safe and does what it is supposed to be.
This presentation will provide a basic overview of clinical research process.
History and evolution in clinical researchRadhika Nagare
Let's start with the famous quote of Aldous Huxley : "The charm of history and its enigmatic lesson consist in the fact that, from age to age, nothing changes and yet everything is completely different."
Chesapeake IRB: The evolution of ethics in clinical researchChesapeake IRB
This presentation is about the evolution of the Declaration of Helsinki, and it is appropriate to note that, indeed, all of ethics is an evolution – a continual discovery.
The Role of Patients & their Challenges in Clinical TrialsKathi Apostolidis
What are clinical trials
Myths about clinical trials
What patients want
The role of patients in clinical trials
How to communicate trial information
How to communicate trial results
This Presentation is about why CRO/Vendor oversight should support sponsor regulatory requirements and cost containment.
Topics covered:
1.Importance of CRO/Vendor oversight in clinical trial management.
2. Identify the ways to integrate a risk-based approaches to CRO/Vendor oversight.
3. Developing a CRO/Vendor oversight plan with appropriate KPIs/metrics to be measured.
4. Use of tools and technology for accurate and timely reporting.
The slide provides a basic understanding about Clinical Research process and the various Phases of Drug Discovery and Development. It also explains about the various trial designs and techniques in research such as blinding and randomization. It may be useful for giving a basic class for Fourth Year B.Pharm Students.
Discover the innovative and creative projects that highlight my journey throu...dylandmeas
Discover the innovative and creative projects that highlight my journey through Full Sail University. Below, you’ll find a collection of my work showcasing my skills and expertise in digital marketing, event planning, and media production.
Business Valuation Principles for EntrepreneursBen Wann
This insightful presentation is designed to equip entrepreneurs with the essential knowledge and tools needed to accurately value their businesses. Understanding business valuation is crucial for making informed decisions, whether you're seeking investment, planning to sell, or simply want to gauge your company's worth.
Memorandum Of Association Constitution of Company.pptseri bangash
www.seribangash.com
A Memorandum of Association (MOA) is a legal document that outlines the fundamental principles and objectives upon which a company operates. It serves as the company's charter or constitution and defines the scope of its activities. Here's a detailed note on the MOA:
Contents of Memorandum of Association:
Name Clause: This clause states the name of the company, which should end with words like "Limited" or "Ltd." for a public limited company and "Private Limited" or "Pvt. Ltd." for a private limited company.
https://seribangash.com/article-of-association-is-legal-doc-of-company/
Registered Office Clause: It specifies the location where the company's registered office is situated. This office is where all official communications and notices are sent.
Objective Clause: This clause delineates the main objectives for which the company is formed. It's important to define these objectives clearly, as the company cannot undertake activities beyond those mentioned in this clause.
www.seribangash.com
Liability Clause: It outlines the extent of liability of the company's members. In the case of companies limited by shares, the liability of members is limited to the amount unpaid on their shares. For companies limited by guarantee, members' liability is limited to the amount they undertake to contribute if the company is wound up.
https://seribangash.com/promotors-is-person-conceived-formation-company/
Capital Clause: This clause specifies the authorized capital of the company, i.e., the maximum amount of share capital the company is authorized to issue. It also mentions the division of this capital into shares and their respective nominal value.
Association Clause: It simply states that the subscribers wish to form a company and agree to become members of it, in accordance with the terms of the MOA.
Importance of Memorandum of Association:
Legal Requirement: The MOA is a legal requirement for the formation of a company. It must be filed with the Registrar of Companies during the incorporation process.
Constitutional Document: It serves as the company's constitutional document, defining its scope, powers, and limitations.
Protection of Members: It protects the interests of the company's members by clearly defining the objectives and limiting their liability.
External Communication: It provides clarity to external parties, such as investors, creditors, and regulatory authorities, regarding the company's objectives and powers.
https://seribangash.com/difference-public-and-private-company-law/
Binding Authority: The company and its members are bound by the provisions of the MOA. Any action taken beyond its scope may be considered ultra vires (beyond the powers) of the company and therefore void.
Amendment of MOA:
While the MOA lays down the company's fundamental principles, it is not entirely immutable. It can be amended, but only under specific circumstances and in compliance with legal procedures. Amendments typically require shareholder
As a business owner in Delaware, staying on top of your tax obligations is paramount, especially with the annual deadline for Delaware Franchise Tax looming on March 1. One such obligation is the annual Delaware Franchise Tax, which serves as a crucial requirement for maintaining your company’s legal standing within the state. While the prospect of handling tax matters may seem daunting, rest assured that the process can be straightforward with the right guidance. In this comprehensive guide, we’ll walk you through the steps of filing your Delaware Franchise Tax and provide insights to help you navigate the process effectively.
Unveiling the Secrets How Does Generative AI Work.pdfSam H
At its core, generative artificial intelligence relies on the concept of generative models, which serve as engines that churn out entirely new data resembling their training data. It is like a sculptor who has studied so many forms found in nature and then uses this knowledge to create sculptures from his imagination that have never been seen before anywhere else. If taken to cyberspace, gans work almost the same way.
Taurus Zodiac Sign_ Personality Traits and Sign Dates.pptxmy Pandit
Explore the world of the Taurus zodiac sign. Learn about their stability, determination, and appreciation for beauty. Discover how Taureans' grounded nature and hardworking mindset define their unique personality.
Putting the SPARK into Virtual Training.pptxCynthia Clay
This 60-minute webinar, sponsored by Adobe, was delivered for the Training Mag Network. It explored the five elements of SPARK: Storytelling, Purpose, Action, Relationships, and Kudos. Knowing how to tell a well-structured story is key to building long-term memory. Stating a clear purpose that doesn't take away from the discovery learning process is critical. Ensuring that people move from theory to practical application is imperative. Creating strong social learning is the key to commitment and engagement. Validating and affirming participants' comments is the way to create a positive learning environment.
Remote sensing and monitoring are changing the mining industry for the better. These are providing innovative solutions to long-standing challenges. Those related to exploration, extraction, and overall environmental management by mining technology companies Odisha. These technologies make use of satellite imaging, aerial photography and sensors to collect data that might be inaccessible or from hazardous locations. With the use of this technology, mining operations are becoming increasingly efficient. Let us gain more insight into the key aspects associated with remote sensing and monitoring when it comes to mining.
3.0 Project 2_ Developing My Brand Identity Kit.pptxtanyjahb
A personal brand exploration presentation summarizes an individual's unique qualities and goals, covering strengths, values, passions, and target audience. It helps individuals understand what makes them stand out, their desired image, and how they aim to achieve it.
What is the TDS Return Filing Due Date for FY 2024-25.pdfseoforlegalpillers
It is crucial for the taxpayers to understand about the TDS Return Filing Due Date, so that they can fulfill your TDS obligations efficiently. Taxpayers can avoid penalties by sticking to the deadlines and by accurate filing of TDS. Timely filing of TDS will make sure about the availability of tax credits. You can also seek the professional guidance of experts like Legal Pillers for timely filing of the TDS Return.
Enterprise Excellence is Inclusive Excellence.pdfKaiNexus
Enterprise excellence and inclusive excellence are closely linked, and real-world challenges have shown that both are essential to the success of any organization. To achieve enterprise excellence, organizations must focus on improving their operations and processes while creating an inclusive environment that engages everyone. In this interactive session, the facilitator will highlight commonly established business practices and how they limit our ability to engage everyone every day. More importantly, though, participants will likely gain increased awareness of what we can do differently to maximize enterprise excellence through deliberate inclusion.
What is Enterprise Excellence?
Enterprise Excellence is a holistic approach that's aimed at achieving world-class performance across all aspects of the organization.
What might I learn?
A way to engage all in creating Inclusive Excellence. Lessons from the US military and their parallels to the story of Harry Potter. How belt systems and CI teams can destroy inclusive practices. How leadership language invites people to the party. There are three things leaders can do to engage everyone every day: maximizing psychological safety to create environments where folks learn, contribute, and challenge the status quo.
Who might benefit? Anyone and everyone leading folks from the shop floor to top floor.
Dr. William Harvey is a seasoned Operations Leader with extensive experience in chemical processing, manufacturing, and operations management. At Michelman, he currently oversees multiple sites, leading teams in strategic planning and coaching/practicing continuous improvement. William is set to start his eighth year of teaching at the University of Cincinnati where he teaches marketing, finance, and management. William holds various certifications in change management, quality, leadership, operational excellence, team building, and DiSC, among others.
Attending a job Interview for B1 and B2 Englsih learnersErika906060
It is a sample of an interview for a business english class for pre-intermediate and intermediate english students with emphasis on the speking ability.
Affordable Stationery Printing Services in Jaipur | Navpack n PrintNavpack & Print
Looking for professional printing services in Jaipur? Navpack n Print offers high-quality and affordable stationery printing for all your business needs. Stand out with custom stationery designs and fast turnaround times. Contact us today for a quote!
2. • Clinical trials are sets of tests in medical,
medical research and drug development that
generate safety and efficacy data (information
about adverse drug reactions and adverse
effects of other treatments) for health
interventions (e.g., drugs, diagnostics, devices,
therapy protocols).
3. History of CT before yr 1750
• Persian physician and philosopher, Avicenna
• In The Canon of Medicine, he laid down rules
for the experimental use and testing of
drugs and wrote a precise guide for practical
experimentation in the process of discovering
and proving the effectiveness of
medical drugs and substances. He laid out the
following rules and principles for testing the
effectiveness of new drugs and medications.
4. Earlier rules
1. The drug must be free from any extraneous accidental quality.
2. It must be used on a simple, not a composite, disease.
3. The drug must be tested with two contrary types of diseases,
because sometimes a drug cures one disease by its essential
qualities and another by its accidental ones.
4. The quality of the drug must correspond to the strength of the
disease.
5. The time of action must be observed, so that effect and
accident are not confused.
6. The effect of the drug must be seen to occur constantly or in
many cases, for if this did not happen, it was an accidental
effect.
7. The experimentation must be done with the human body, for
testing a drug on a lion or a horse might not prove anything
about its effect on man.
5. History
Perhaps the first ever clinical trial was James Lind’s
demonstration in 1753 that citrus fruits cured scurvy. He
compared the effects of various different acidic
substances ranging from vinegar to cider, on groups of
sailors, and found that the group who were given
oranges and lemons had largely recovered from scurvy
after 6 days.
6. • Before one can initiate testing in human beings, they must
conduct extensive pre-clinical or laboratory research.
• Research usually involves years of experiments in animal and
human cells.
• If this stage of testing is successful, the sponsor then provides
this data to the FDA requesting approval to being testing in
humans. This is called an Investigational New Drug Application
(IND)
• If approved by the FDA, testing in humans begins. This is done
through a formally written and approved protocol.
7. What is a Protocol?
• A study plan on which all clinical trials are based.
• Carefully designed to protect the health of participants
• Describes what types of people may participate in the trial
(inclusion and exclusion criteria)
• Gives detailed schedule of tests, procedures, medications,
dosages, and length of the study.
• Principal Investigator is responsible for assuring that the
protocol is strictly followed for each participant
8. Randomization of trials
• Researchers assign patients by chance to either a group taking
the new diagnostic or treatment agent. Similar to “flipping a
coin”.
• Randomization helps avoid bias.
• The assigned groups are often referred to as “arms”.
Example: Patient #1 is assigned to Arm A of the trial,
which involves the new modality or treatment.
Patient #2 is assigned to Arm B, which is the standard
modality or treatment.
9. What is a Blinded Study?
• In a single blinded study, the patient does not know which arm
of the protocol they have been assigned to.
• This approach avoids bias because when people know what
they are taking, it might change the way they react.
Example: Patients who know that they are assigned to the
“new treatment” group might expect it to work better and
report hopeful signs because they want to believe they
are getting well. This could bias the study by making
results look better than they are.
10. CONT…
• Double blinded studies are those studies where neither the
patient or the research physician know whether the patient is
receiving the actual study drug or standard drug.
• When no standard is available, some studies compare new
drugs with placebo drugs.
• All patients are informed of the possibility of being assigned to
the placebo arm of a study
• Patients are “unblinded” only if it becomes medically
necessary prior to the end of the study.
11. Who Sponsors Clinical Trials?
• Physicians
• Medical Institutions
• Foundations
• Voluntary Groups
• Pharmaceutical Companies
• Federal Agencies (cooperative group
research)
– NIH
12. TYPES of CT
The most commonly performed clinical
trials evaluate new drugs, medical
devices, biologics, or other interventions
on patients in strictly scientifically
controlled settings, and are required for
regulatory authority approval of new
therapies.
13. Types of CT
• One way of classifying clinical trials is by the way the
researchers behave.
• In an observational study, the investigators observe the
subjects and measure their outcomes. The researchers
do not actively manage the study.
• In an interventional study, the investigators give the
research subjects a particular medicine or other
intervention. Usually, they compare the treated
subjects to subjects who receive no treatment or
standard treatment. Then the researchers measure
how the subjects' health changes.
14. Types of CT
• NIH organizes trials into 5 different categories.
• Treatment Trials- test experimental treatments, new
combinations of drugs, or new approaches to
surgery or radiology/radiation therapy.
• Prevention Trials- look for better ways to prevent
disease in people who have never had them or
prevent them from returning.
• Diagnostic Trials- conducted to find better tests or
procedures for diagnosing a particular disease or
condition.
• Screening Trials- test the best way to detect certain
diseases or health conditions.
• Quality of Life- explore ways to improve comfort and
the quality of life for individuals with chronic illness
17. Toxicological studies
• Acute toxicity (Graded dose and 1 or 2 animal species)
• Subacute toxicity (3 dose and 2 animal species)
• Chronic toxicity (3 dose and 2 animal (1 rodent and
other non rodent)
• Special toxicity:
i. Effect on reproductive performance
ii. Teratogenicity
iii. Carcinogenicity (Same dose for 2 yrs)
iv. Mutagenicity : AMES Test (S.Typhi, Histidine medium)
v. Local toxicity: dermal, ocular, vaginal etc
20. Human Clinical Trial
• Human ethical committee: 2+5
• 2: 1 member secretary, 1 chairman from
outside Institute.
• 5: 1 medical doctor, 1 Pharmacologist, 1
socially aware member, 1 lawyer, 1 lay person
from society.
• Informed consent: verbal as well as written
Time period: 5-7 yrs
21.
22. Phase 0
• Conducted in accordance with the United
States Food and Drug Administration's (FDA)
2006.
• Microdosing studies
• Administration of single sub therapeutic doses
• Small number of subjects (10 to 15)
• Provides agent's pharmacodynamics
and pharmacokinetics
• Companies: go/ no-go decisions
23. Phase I
• Pharmacologists & employees (25-100 in number)
ethical approval
• healthy
• informed consent
• Medical backup
• Monitor
• Three different kinds of Phase I trials include:
– SAD-single ascending dose studies
– MAD-multiple ascending dose studies
– Food Effect-investigates differences in absorption
caused by eating pre-dose
24. Objectives
• To check whether animal and human show
any differences
• Tolerated dose range (Pharmacovigilance),
• Pharmacokinetics, Variability between
individuals; effect of route; bioavailability
• Indication of therapeutic effects
• Indication of side effects
The trial is open labelled and non blind
25. Single ascending dose studies (SAD)
• SAD those in which small groups (3) of subjects
are given a single dose of the drug while they are
observed and tested for a period of time.
• If no adverse effects, dose is escalated with 3 new
healthy subjects
• If toxicity is obs. then 3 more subjects are given
the same dose and if found toxic, the dose is
considered as max. tolerated dose (MTD).
26. Multiple ascending dose (MAD)
• MAD are conducted to understand the
pharmacokinetics and pharmacodynamics of
multiple doses of the drug.
• A group of patients receives multiple low
doses of the drug
• Samples (of blood, and other fluids) are
collected at various time points
• Analyzed: How the drug is processed within
the body.
27. Food effects
• A short trial designed to investigate any
differences in absorption of the drug by the
body, caused by eating before the drug is
given.
28. Phase II
• 150-350 ill people; informed
consent
• End point is decided
• Maximum monitoring
• Often patients where other
treatment failed
• Early phase : 200 patients, single
blind
• Late Phase: 200-400, controlled
double blind
Once a drug has shown to be safe, then it must be tested for efficacy.
This phase may last from several months to two years.
Most of these trials are randomized trials
29. Objectives
Indication for use; type of patient;
severity of disease; dose range,
schedule and increment; pharmacokinetic studies in ill people;
Nature of side effects and severity; Effects in special groups.
30. Phase III
• 1500-3500 ill patients
• Multicentre
• Randomized
• Double blind
• More certain data from the objectives of phase 2
studies
• Interactions between drugs start to become
measurable in the larger population
• Sub-groups start to be established
• Special features and problems show up
31. Single arm trial
• Simplest CT
• Only one treatment
When drug is studied for the first time
When population is homologous
When there is no other therapy available
When placebo is not recommended
Eg TD1 to only one group of patient
32. Parallel group study
• When each of the grp receives a single
therapy simultaneously.
• Eg Grp I: tment A
• Grp II: tment B or control
34. Double blind cross over design of
Phase III trial
Patient group Week 1 Week 2 Week 3
I SD TD ND
II TD ND SD
III ND SD TD
35. Factorial design study
• Used when combination of drugs are to be given
• Eg in HIV
• Eg 3 gps
• A: TD1
• B:TD2
• C:TD1+TD2
• D: No tment
• Results are difficult to interpret
36. • Sponsorer can file the application for NDA
• Complete Monograph, insert etc
37. Phase IV
• After approval for marketing
• Post Licensing phase
• No fixed duration
• To find the rare side effects, congenital
effects,drug-drug interactions, safety studies,
mortality studies, epidemiological studies.
• PERIODIC SAFETY UPDATE REPORTS
• To be submitted by the manufacturer every 6
months for 2 yrs and then annually for next 2 yrs.
38. The refocoxib story
• Rofecoxib , anti-inflammatory drug (NSAID) that has now been
withdrawn over safety concerns. It was marketed by Merck &
Co. to treat osteoarthritis, acute pain conditions,
and dysmenorrhoea.
• Rofecoxib – FDA-on May 20, 1999, brand names Vioxx, Ceoxx,
and Ceeoxx.
• Rofecoxib used widely for arthritis and other conditions causing
chronic or acute pain. Worldwide, over 80 million people were
prescribed rofecoxib at some time.
• On September 30, 2004, Merck withdrew rofecoxib from the
market
• Increased risk of heart attack and stroke associated with long-term,
high-dosage use.
• Merck withdrew but the drug resulted in between 88,000 and
140,000 cases of serious heart disease
• US$2.5 billion in 5 yrs
39. Time required
S.no Phases Time period {yrs}
1 Drug discovery 2-5
2 Preclinical 1.5-2
3 Clinical 5-7
4 Regulatory 1.5
5 Phase IV 4
Total Approx 20 yrs
41. Investigational New Drug Application
• Current Federal law requires that a drug be
approved for marketing application before it is
transported or distributed across state lines.
• But in case of investigational drug, it is
required by clinical investigators in many
states.
• IND is an exemption.
42. • FDA's role in the development of a new drug
begins when the drug's sponsor (usually the
manufacturer or potential marketer) having
screened the new molecule for
pharmacological activity and acute toxicity
potential in animals, wants to test its
diagnostic or therapeutic potential in
humans. At that point, the molecule changes
in legal status under the Federal Food, Drug,
and Cosmetic Act and becomes a new drug
subject to specific requirements of the drug
regulatory system.
44. Manufacturing Information
Composition, manufacturer, stability, and
controls used for manufacturing the drug
substance and the drug product.
This information is assessed to ensure that the
company can adequately produce and supply
consistent batches of the drug.
Lic form-29 is taken for mfg of new drug
45. Clinical Protocols and Investigator
Information
• Detailed protocols for proposed clinical studies to
assess whether the initial-phase trials will expose
subjects to unnecessary risks.
• Information on the qualifications of clinical trial
team.
• Informed consent from the research subjects,
• to obtain review of the study by an institutional
review board (IRB),
• Adherence to the investigational new drug
regulations.
46. Review by FDA
• Once the IND is submitted, the sponsor must
wait 30 calendar days before initiating any
clinical trials. During this time, FDA
(DCGI/CDSCO) has an opportunity to review
the IND for safety to assure that research
subjects will not be subjected to unreasonable
risk.
47. Summary
• An application to conduct clinical trials in India
should be submitted along with the data of
chemistry, manufacturing, control and animal
studies to DCGI. The date regarding the trial
protocol, investigator's brochures, and informed
consent documents should also be attached. A
copy of the application must be submitted to the
ethical committee and the clinical trials are
conducted only after approval of DCGI and ethical
committee. To determine the maximum tolerated
dose in humans, adverse reactions, etc.
48. New Drug Application
• The new drug registration (using form no. 44 along with full
pre-clinical and clinical testing information) is applied after
the completion of clinical trials.
• The comprehensive information on the marketing status of
the drug in other countries is also required other than the
information on safety and efficacy.
• The information regarding the prescription, samples and
testing protocols, product monograph, labels,
and cartons must also be submitted.
• Schedule Y of D&C act, provides the guidelines and
requirements for clinical trials.
• The application can be reviewed in a range of about 12- 18
months
• Then the permission is granted.
49. Regulatory bodies in World
• USA: FDA, Dept of health and human services
• Canada: Health Canada
• UK: Medicines and Healthcare products
regulatory agency (MHRA)
• EU: European Medicines Agency (EMEA)
• Japan: Pharmaceutical and Medical Devices
agencies (PMDA)
• India:
50. Regulating bodies in India
• The Drug and Cosmetic Act 1940 and Rules
1945 were passed by the India's parliament to
regulate the import, manufacture, distribution
and sale of drugs and cosmetics.
• The Central Drugs Standard Control
Organization (CDSCO),
• The Drugs Controller General (India) [DCGI]
was established.
52. Regulatory requirements for clinical
trials
Before starting trial
• Consent of investigator
• Approval by IRB..approval of protocol, site,
• Approval from ICMR in case of new molecules
developed in India
• Informed consent
• Insurance cover for trial related injury
53. During the conduct
• Compliance with the trial protocol
• Reporting protocol violations to EC
• Seek approval for protocol amendments
• Adherence to GCP
• Record all adverse effects
• Record of all serious adverse effects to sponsor in
24 hr
• Notification of fatal adv effect to RB
• Review the progress of results of study
• Send periodic status of study.
54. Post trial requirement
• Site close out
• Check investigational product utilization
• Analyze the data using statistical softwares
• Forward the report from investigator to EC
• Seek new drug approval.
• Prepare and submit the prescribing
information for ND to the authorities
55. Newly approved drugs
• Gilotrif (afatinib) Tablets: for lung cancer
Boehringer Ingelheim Pharmaceuticals
• Khedezla (desvenlafaxine): for depression
Osmotica Pharmaceutical Corp.